FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
23/04/2024
Voltar para busca
Dado oficial do USPTO
BI-CYGNI
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
23/04/2024
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
22/02/2022
Data de registro
19/12/2023
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
19/12/2023
Última transação
19/12/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
KOVALSKY, LAURA G
Unidade examinadora
M10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
BIVICTRIX LIMITED
Representantes
Leon R. Legleiter KDW Firm PLLC
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Antibodies for medical purposes; anti-cancer drugs; anti-cancer preparations; anti-cancer preparations of chemical origin; anti-cancer preparations of plant origin; anti-infective antibiotics; anti-infective preparations; anti-infectives; anti-inflammatories; antiparasitic preparations; anti-viral agents; biological adjuvants for medical purposes; biological preparations for medical purposesnamely for the treatment of cancer; biological preparations for the treatment of cancer; biological preparations for veterinary purposes; biological diagnostic reagents for medical use; biological diagnostic reagents for veterinary use; biological tissue cultures for medical purposes; biopharmaceutical preparations for the treatment of cancer; biotechnological preparations for medical use for the treatment of cancer; blood components in the nature of blood protein fractionsblood cellular fractionsblood plasma and cord blood for medical purposes; cardiovascular pharmaceutical preparations; cardiovascular preparations; cells for medical use; cellular function activating agents for medical purposes; chemical adjuvants for medical purposes; chemical preparations for medical purposesnamely for prevention or treatment of cancer; chemical preparations for pesticidal purposespesticides; chemical preparations for pharmaceutical purposes namely for prevention or treatment of cancer; chemical preparations for testing blood for medical purposes; chemical reagents for medical use; chemical preparations for pharmaceutical usenamely for prevention or treatment of cancer; chemotherapeutics; clinical diagnostic reagents for medical use; clinical medical reagents; pharmaceutical compounds for treating cancer; pharmaceutical compounds for treating correlated pulmonary syndromes; pharmaceutical compounds for treating respiratory diseases; cord blood for medical purposes; culture media for use in treatment of cancer for medical use; cultures of microorganisms and mammalian cultures for medical use; cytostatic drugs for medical purposes; cytostatics for medical purposes; cytostatics for pharmaceutical purposes; diagnostic agents for medical use; diagnostic agents for pharmaceutical use; diagnostic biomarker reagents for medical purposes; diagnostic chemical reagents for medical use; diagnostic preparations for medical use; diagnostic preparations and materials in the nature of cancer diagnostics for medical purposes; diagnostic preparations for medical and veterinary use; diagnostic preparations for medical or veterinary purposes; diagnostic preparations for medical purposes; diagnostic reagents for medical use; diagnostic reagents for medicinal use; diagnostic substances for medical use; diagnostic testing materials in the natural of cancer diagnostics for medical use; drugs for medical purposesnamely cancer treatment; haemostatic preparations in the nature of medical haemostatic pastehaemostatic pencils; homeopathic medicines in the nature of pharmaceuticals for use in the treatment of cancer; immunomodulators; immunostimulants; immunosuppressants for use following transplantation in the case of graft rejection; immunotherapeutic agents for bacterial infections; in vitro diagnostic preparations for medical use; living cells for medical use; living cells for veterinary use; medicinesmedicines for cancer disorders; medicines for human purposescancer medicines; medicines for intestinal disorders; medicines for the treatment of gastrointestinal diseases; medicines for treating intestinal disorders; pain relief preparations in the nature of pain relief medication; pharmaceutical compositionspreparations for the treatment of cancer; pharmaceutical drugspreparations for the treatment of cancer; pharmaceutical preparationspreparations for the treatment of cancer; pharmaceutical preparations and substancespreparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations and substances for the treatment of cancer; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations and substances for use in gynecology; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for use in the field of anesthesia; pharmaceutical preparations and substances for use in urology; pharmaceutical preparations and substances with anti-inflammatory properties; pharmaceutical preparations and substances with antipyretic properties; pharmaceutical preparations for activating cellular function; pharmaceutical preparations for human usepreparations for the treatment of cancer; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for medical purposespreparations for the treatment of cancer; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the prevention of allergies; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of diseases caused by bacteria; pharmaceutical preparations for the prevention of diseases of the cardio-vascular system; pharmaceutical preparations for the prevention of diseases of the endocrine system; pharmaceutical preparations for the prevention of diseases of the genitourinary system; pharmaceutical preparations for the prevention of diseases of the immune system; pharmaceutical preparations for the prevention of diseases of the metabolic system; pharmaceutical preparations for the prevention of diseases of the musculo-skeletal system; pharmaceutical preparations for the prevention of diseases of the nervous system; pharmaceutical preparations for the prevention of diseases of the respiratory system; pharmaceutical preparations for the prevention of disorders caused by bacteria; pharmaceutical preparations for the prevention of disorders of the cardio-vascular system; pharmaceutical preparations for the prevention of disorders of the endocrine system; pharmaceutical preparations for the prevention of disorders of the genitourinary system; pharmaceutical preparations for the prevention of disorders of the immune system; pharmaceutical preparations for the prevention of disorders of the metabolic system; pharmaceutical preparations for the prevention of disorders of the musculo-skeletal system; pharmaceutical preparations for the prevention of disorders of the nervous system; pharmaceutical preparations for the prevention of disorders of the respiratory system; pharmaceutical preparations for the prevention of inflammatory diseases; pharmaceutical preparations for the prevention of inflammatory disorders; pharmaceutical preparations for the prevention of ocular diseases; pharmaceutical preparations for the prevention of ocular disorders; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the prevention of tumours; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of autoimmune disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for the treatment of central nervous system diseases; pharmaceutical preparations for the treatment of digestive diseases; pharmaceutical preparations for the treatment of diseases caused by bacteria; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of diseases of the genitourinary system; pharmaceutical preparations for the treatment of diseases of the metabolic system; pharmaceutical preparations for the treatment of diseases of the musculo-skeletal system; pharmaceutical preparations for the treatment of disorders caused by bacteria; pharmaceutical preparations for the treatment of disorders of the endocrine system; pharmaceutical preparations for the treatment of disorders of the genitourinary system; pharmaceutical preparations for the treatment of disorders of the metabolic system; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of esophagitis; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hormonal disorders; pharmaceutical preparations for the treatment of hypercholesteremia; pharmaceutical preparations for the treatment of hyperlipidemia; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of inflammatory diseases; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of musculo-skeletal disorders; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for the treatment of Parkinson's disease; pharmaceutical preparations for the treatment of tumours; pharmaceutical preparations for the treatment of viral diseases; pharmaceutical preparations for treating allergic rhinitis; pharmaceutical preparations for treating allergies; pharmaceutical preparations for treating arthritis; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating chemical imbalances; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating digestive system disorders; pharmaceutical preparations for treating epidermal problems; pharmaceutical preparations for treating gastrointestinal disorders; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for treating hypoglycemia; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for treating rheumatological diseases; pharmaceutical preparations for treating sensory organ disorders; pharmaceutical preparations for treating skeletal diseases; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for treating the symptoms of radiation sickness; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in hematology; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for use in organ transplantation; pharmaceutical preparations for use in tissue transplantation; pharmaceutical preparations for use in urology; pharmaceutical preparations for veterinary use for the prevention and treatment of cancer; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of cancer; pharmaceutical products for the treatment of infectious diseases; pharmaceutical products for the treatment of viral diseases; pharmaceutical products for treating respiratory diseases; pharmaceuticals and natural remedies for the prevention and treatment of cancer; pharmacological preparations for skin care; preparations for the treatment of asthma; radioactive substances for medical purposes; radio-isotope markers for therapeutic or diagnostic use; radiological contrast substances for medical purposes; radiopharmaceutical productspharmaceutical products for the prevention and treatment of cancer; clinical medical reagents for analytical purposes; clinical reagents for veterinary or medicalanalytical purposes; clinical medical reagents for in-vitro laboratory use; clinical veterinary reagents for in-vitro laboratory use; clinical reagents for medical use; clinical medical reagents for use in diagnostic tests; clinical veterinary reagents for use in diagnostic tests; reconstituted cells for clinical treatments for skin care; reconstituted cells for medical treatments for skin care; tissue-regenerative pharmaceutical preparations; tissues for medical use in the nature of biological tissue grafts and human allograft tissue
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
28/03/2024
FIMP
FINAL DISPOSITION PROCESSED
28/03/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
19/03/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
19/12/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
19/12/2023
GPNX
NOTIFICATION PROCESSED BY IB
04/10/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
03/10/2023
PUBO
PUBLISHED FOR OPPOSITION
03/10/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
13/09/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
13/09/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
13/09/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
25/08/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
25/08/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
25/08/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
25/08/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
25/08/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/08/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/08/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/08/2023
RFNP
REFUSAL PROCESSED BY IB
28/02/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/02/2023
RFRR
REFUSAL PROCESSED BY MPU
07/02/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
13/12/2022
CNRT
NON-FINAL ACTION WRITTEN
12/12/2022
DOCK
ASSIGNED TO EXAMINER
06/12/2022
MAFR
APPLICATION FILING RECEIPT MAILED
06/09/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/09/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/09/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace BI-CYGNI ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.